Prominent Pulmonary Or Respiratory Drug Delivery Market Driver for 2025: Impact Of Rising Pneumonia Cases On The Growth Of Market

What Are the Projected Growth and Market Size Trends for the Pulmonary Or Respiratory Drug Delivery Market?
Recent years have seen a significant increase in the size of the pulmonary or respiratory drug delivery market. The projections are that this market's value will ascend from $69.83 billion in 2024 to $76.38 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%. Growth in the historical period is largely due to factors such as the increased occurrence of asthma, the growing usage of innovative inhalation devices, the expansion in global healthcare spending, heightened knowledge of respiratory diseases, and the escalating incidence of allergy-related conditions.

The market size for pulmonary or respiratory drug delivery is set to experience robust expansion in the upcoming years. It is projected to reach a value of $107.85 billion in 2029, with a compound annual growth rate (CAGR) of 9.0%. The projected growth during this period can be linked to the surge in demand for personalized medicine, increase in chronic respiratory disease cases, heightened focus on telemedicine, augmented investments in healthcare infrastructure, and e-commerce growth in the pharmaceutical sector. Future trends for the forecast period include enhancements in particle engineering, the evolution of sophisticated nebulizers, creation of liposomal formulations, advancements in computational fluid dynamics, and the production of smart inhalers.

What Is Driving the Growth Trajectory of the Pulmonary Or Respiratory Drug Delivery Market?
The rising incidence of pneumonia is set to fuel the growth of the pulmonary or respiratory drug delivery market. Pneumonia is an infection that inflames the air sacs in the lungs which can fill with fluid or pus, causing symptoms such as coughing, fever, and breathing difficulties. Factors such as growing elderly populations, compromised immune systems, respiratory infections, pollution, smoking, and the emergence of antibiotic-resistant bacteria are driving the increase in pneumonia cases. Pulmonary or respiratory drug delivery methods help patients afflicted with pneumonia by directly delivering medications such as antibiotics, bronchodilators, or anti-inflammatory agents to the lungs. This enables a quicker and more efficient treatment that alleviates symptoms, reduces inflammation, clears infections and enhances respiratory function, ultimately speeding up recovery and preventing complications. For example, the Centre for Tropical Medicine and Global Health, a leading UK-based health research organization, reported in November 2023, that pneumonia cases in Kenya had surged dramatically, hitting 793,864 in 2022/2023. Consequently, the rising incidence of pneumonia is driving the growth of the pulmonary or respiratory drug delivery market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

Which Leading Companies Are Shaping the Growth of the Pulmonary Or Respiratory Drug Delivery Market?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

What Are the Latest Innovations in the Pulmonary Or Respiratory Drug Delivery Market?
In the pulmonary or respiratory drug delivery market, leading companies are prioritizing technological improvements, such as intricate drug delivery systems, to amplify the effectiveness of treatments and patient adherence. Such complex drug delivery mechanisms utilize cutting-edge technology to boost targeted drug delivery and controlled therapeutic agent release, augmenting both drug efficacy and patient results. For example, Viatris Inc., a US healthcare company that produces both generic and branded medicines, along with Kindeva Drug Delivery L.P., launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol in July 2023. The inhalation aerosol, endorsed by the Food and Drug Administration, is the inaugural generic edition of AstraZeneca's Symbicort. It is a metered-dose inhaler integrating budesonide and formoterol for the treatment of asthma and chronic obstructive pulmonary disease, available in 80 micrograms and 160 micrograms strengths including 4.5 micrograms of formoterol.

What Are the Key Segments of the Pulmonary Or Respiratory Drug Delivery Market?
The pulmonary or respiratory drug delivery market covered in this report is segmented -

1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

Which Region Dominates the Pulmonary Or Respiratory Drug Delivery Market?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Pulmonary Or Respiratory Drug Delivery Global Market Report?

- Market Size Analysis: Analyze the pulmonary or respiratory drug delivery Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the pulmonary or respiratory drug delivery Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall pulmonary or respiratory drug delivery market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the pulmonary or respiratory drug delivery market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.